Medical device manufacturer Quanta has selected SMART-TRIAL’s platform for the collection and management of all clinical trial data.
Quanta is improving the lives of dialysis patients by providing advanced haemodialysis solutions for use in both the clinic and home. Quanta’s flagship product SC+ is designed to give dialysis patients greater flexibility, convenience and, control over the delivery of their life-sustaining renal replacement therapy.
“SMART-TRIAL’s disruptive cloud technology helps Quanta’s clinical trial teams to work faster and significantly reduce the costs of generating and managing clinical and operational data, from our perspective, it is transforming our extended data ecosystem.”
said James Grainger, Quanta’s Clinical Study Manager
Quanta is using SMART-TRIAL to collect SC+ data from healthcare professionals and patients. SC+ is a unique small, simple and powerful haemodialysis system that supports patients across the continuum of care, from the clinic to the home. SC+ provides clinical efficacy and high flow rates compatible with traditional treatment regimens used in-center. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The small form factor and simple-to-use design are intended to enable a broader range of users across a wide range of settings.
The medical firm also uses SMART-TRIAL’s cloud to collect SC+ data from patients online devices. By bringing all data together in one intelligent platform, Quanta slashes the time and costs involved in comparing clinical data with operational data.
“Quanta’s clinical and operational-wide use of SMART-TRIAL is another example of how MEDEI is bringing data collection and management innovation to the medical world.”
added Páll Jóhannesson, MEDEI’s CEO.
For further information and images, please contact:
Jon Ingi Bergsteinsson
Vice President for Global Business Development
Tel: +45 42 70 70 03